Non Hodgkin Lymphoma Clinical Trial
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Eligibility Criteria
Inclusion Criteria:
Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible for stem cell transplant
Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment
ECOG 0 to 2
Adequate hematologic, hepatic, and renal functions.
Exclusion Criteria:
Prior treatment with any MDM2 inhibitor
Prior treatment with any BTK inhibitor
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Goshen Indiana, 46526, United States
Cincinnati Ohio, 45221, United States
Columbus Ohio, 43210, United States
Dallas Texas, 75390, United States
Adelaide , , Australia
Box Hill , , Australia
Geelong , , Australia
Perth , , Australia
Edegem , , Belgium
Hasselt , , Belgium
Leuven , , Belgium
Nový Hradec Králové , , Czechia
Ostrava , , Czechia
Prague , , Czechia
Nantes , , France
Rouen , , France
Tours , , France
Aviano , , Italy
Meldola , , Italy
Milano , , Italy
Milano , , Italy
Pavia , , Italy
Verona , , Italy
Goyang , , Korea, Republic of
Incheon , , Korea, Republic of
Seoul , , Korea, Republic of
Seoul , , Korea, Republic of
Seoul , , Korea, Republic of
Seoul , , Korea, Republic of
Gdansk , , Poland
Gdańsk , , Poland
Gliwice , , Poland
Krakow , , Poland
Kraków , , Poland
Wroclaw , , Poland
Braga , , Portugal
Lisboa , , Portugal
Lisbon , , Portugal
Porto , , Portugal
Vila Nova de Gaia , , Portugal
Saint Gallen , , Switzerland
Leeds , , United Kingdom
London , , United Kingdom
London , , United Kingdom
Southampton , , United Kingdom
How clear is this clinincal trial information?